Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease

Trial Profile

Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Eltoprazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Therapeutic Use
  • Sponsors Amarantus Bioscience Holdings
  • Most Recent Events

    • 20 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 20 Apr 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
    • 20 Apr 2016 Status changed from suspended to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top